[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of Guangzhou Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":598},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,48,0,25,[9,52,77,92,112,137,168,196,217,244,274,298,324,349,368,385,405,422,445,472,493,511,537,556,577],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100053219","modified-mini-pcnl-versus-standard-pcnl-for-complex-kidney-stones-100053219",false,"NCT07697677","Modified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones","Modified Mini Percutaneous Nephrolithotomy Versus Standard Percutaneous Nephrolithotomy for the Treatment of Complex Renal Calculi: A Multicenter Randomized Controlled Trial","MIMIC-PCNL","Inclusion Criteria:\n\n1. Adults aged ≥18 years.\n2. Serum creatinine ≤133 μmol\u002FL.\n3. American Society of Anesthesiologists (ASA) physical status classification I-III.\n4. S.T.O.N.E. score ≥8.\n5. Complex renal stones confirmed by noncontrast computed tomography, including stone surface area \\>1500 mm², multiple calyceal stones, partial or complete staghorn calculi, or complex anatomical conditions.\n6. Patients who provide written informed consent and agree to undergo either modified mini-percutaneous nephrolithotomy or standard percutaneous nephrolithotomy.\n\nExclusion Criteria:\n\n1. Solitary kidney.\n2. Morbid obesity (body mass index ≥35 kg\u002Fm²).\n3. Previous renal transplantation or urinary diversion.\n4. Congenital abnormalities of the urinary tract.\n5. Pregnancy.\n6. Uncorrected coagulopathy.\n7. Active urinary tract infection.","ALL","18 Years","70 Years",{"count":22,"type":23},1380,"ESTIMATED","INTERVENTIONAL",[26],"NA","Kidney stones that are large or complex are often treated with percutaneous nephrolithotomy, also called PCNL. Standard PCNL uses a larger access tract and is effective for removing complex kidney stones, but it may be associated with more bleeding, pain, and recovery burden. Modified mini-PCNL uses a smaller access tract and may reduce surgical trauma while maintaining a similar stone clearance rate.\n\nThis multicenter randomized trial will compare modified mini-PCNL using a 20 Fr access sheath with standard PCNL using a 24 Fr access sheath in adults with complex renal stones. About 1,380 participants from 8 urology centers will be randomly assigned to receive one of the two procedures. The main purpose of the study is to determine whether modified mini-PCNL is not worse than standard PCNL in achieving stone-free status shortly after surgery. Stone-free status will be assessed by low-dose noncontrast CT within 72 hours after surgery. The study will also compare stone-free status at 3 months, complications, operation time, length of hospital stay, need for additional procedures, and quality of life.",[29,30],"Kidney Stones","Complex Renal Calculi",[32,33,34,35,36,37,38],"Percutaneous Nephrolithotomy","Mini-PCNL","Standard PCNL","Modified Mini-PCNL","Complex Renal Stones","Stone-Free Rate","Randomized Controlled Trial","RECRUITING","2026-07-07",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":23},"2026-07-15",{"date":47,"type":23},"2027-09-14",{"name":49,"class":50},"The First Affiliated Hospital of Guangzhou Medical University","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100642338","peripheral-blood-cytof-and-viral-imprinting-in-postoperative-multiple-pulmonary-nodules-100642338","NCT07647484","Peripheral Blood CyTOF and Viral Imprinting in Postoperative Multiple Pulmonary Nodules","A Multicenter Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules","Inclusion Criteria:\n\nAge 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.\n\nPlanned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.\n\nAble to understand the study and willing to provide written informed consent before research blood sample collection.\n\nExclusion Criteria:\n\nInvestigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.\n\nAcute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.\n\nCurrent strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.\n\nUnable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.\n\nAny other condition that, in the investigator's judgment, makes participation inappropriate.",{"count":60,"type":23},200,"200 Months","OBSERVATIONAL","This multicenter prospective cohort study will enroll adults who have undergone resection of a primary pulmonary nodule and have residual multiple pulmonary nodules or require routine postoperative pulmonary nodule follow-up. During clinically indicated follow-up visits, a small amount of peripheral venous blood will be collected at the same time as routine blood draws for research CyTOF immune phenotyping and viral imprinting-related serology. The study will not assign participants to treatment, change follow-up schedules, imaging, medication, surgery, or other clinical care. Research laboratory results will not be returned to participants or entered into medical records. The study will describe longitudinal peripheral immune-cell profiles and explore associations among T\u002FB\u002FNK cell phenotypes, T-cell differentiation and senescence\u002Fexhaustion markers, viral imprinting markers, and postoperative residual or new pulmonary nodule evolution.",[65],"Multiple Pulmonary Nodules",[67],"CyTOF","NOT_YET_RECRUITING","2026-06-12",{"date":71,"type":43},"2026-06-15",{"date":73,"type":23},"2026-07",{"date":75,"type":23},"2028-12",{"name":49,"class":50},{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":85,"keywords":86,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":91,"locationsCount":4},"100642174","single-center-cytof-and-viral-imprinting-study-in-postoperative-multiple-pulmonary-nodules-100642174","NCT07647055","Single-Center CyTOF and Viral Imprinting Study in Postoperative Multiple Pulmonary Nodules","A Single-Center Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules","Inclusion Criteria:\n\n* Age 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.\n\nPlanned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.\n\nAble to understand the study and willing to provide written informed consent before research blood sample collection.\n\nExclusion Criteria:\n\n* Investigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.\n\nAcute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.\n\nCurrent strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.\n\nUnable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.\n\nAny other condition that, in the investigator's judgment, makes participation inappropriate.",{"count":60,"type":23},[65],[67],"2026-06-09",{"date":71,"type":43},{"date":73,"type":23},{"date":75,"type":23},{"name":49,"class":50},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":111,"locationsCount":4},"100643439","intelligent-pulmonary-rehabilitation-after-lung-cancer-surgery-100643439","NCT07631520","Intelligent Pulmonary Rehabilitation After Lung Cancer Surgery","A Multicenter Randomized Controlled Trial of an Intelligent Pulmonary Function Exercise Device Versus Usual Care for In-Hospital and Home-Based Pulmonary Rehabilitation After Lung Cancer Surgery","Inclusion Criteria:\n\n* 1\\. Age 18 to 75 years. 2. Pathologically confirmed primary non-small cell lung cancer. 3. Scheduled to undergo elective thoracoscopic lobectomy or sublobar resection. 4. Able to understand the study and voluntarily sign written informed consent before surgery.\n\n  5\\. Able to communicate and complete study assessments and postoperative follow-up.\n\n  6\\. Able to use a smartphone independently or with assistance from a caregiver for training records.\n\n  7\\. Good lung re-expansion on postoperative chest imaging. 8. No chest tube drainage or no persistent air leak from chest tube drainage. 9. Clinical stage cT1-T2b, N0-N1, M0, stage IA-IIB. 10. Home environment allows safe training.\n\nExclusion Criteria:\n\n* 1\\. Preoperative measured FEV1 less than 50% of predicted value. 2. Severe cardiopulmonary dysfunction or other conditions judged unsuitable for respiratory training.\n\n  3\\. Previous thoracic surgery or major thoracic trauma. 4. Significant cognitive impairment or psychiatric disorder that prevents cooperation with the study.\n\n  5\\. Pregnancy or breastfeeding. 6. Recent severe infection or active pulmonary disease.","75 Years",{"count":60,"type":23},[26],"This study will compare an intelligent pulmonary function exercise device with usual care and natural recovery in patients recovering from lung cancer surgery.\n\nAfter lung cancer surgery, many patients have reduced lung function, shortness of breath, lower exercise tolerance, and a risk of postoperative pulmonary complications. Standard care usually includes postoperative nursing, pain control, coughing and sputum clearance instruction, early mobilization, discharge education, and routine follow-up. However, patients often lack structured guidance, feedback, and monitoring after discharge.\n\nParticipants in this study will be randomly assigned to one of two groups. One group will use an intelligent pulmonary function exercise device for respiratory training during hospitalization and at home until 30 days after surgery. The prescribed training is two sessions per day, with each session including 30 expiratory training repetitions and 30 inspiratory training repetitions. The device records training completion and related training information and provides reminders and feedback. The other group will receive usual perioperative care, standard discharge education, and natural recovery follow-up without a study-specified respiratory training device or training prescription.\n\nThe main purpose of the study is to determine whether the intelligent pulmonary function exercise device improves recovery of forced expiratory volume in 1 second, or FEV1, from before surgery to 30 days after surgery. The study will also evaluate lung function at 90 days, symptoms, quality of life, walking capacity, training adherence, and postoperative complications.",[104],"Non-Small Cell Lung Cancer","2026-06-02",{"date":107,"type":43},"2026-06-08",{"date":109,"type":23},"2026-06",{"date":75,"type":23},{"name":49,"class":50},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":122,"studyType":62,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100643772","a-study-to-evaluate-the-diagnostic-performance-of-portable-oscillometry-across-chronic-respiratory-diseases-100643772","NCT07631507","A Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases","Inclusion Criteria:\n\n* COPD group:\n\n  * Age：≥40\n  * Suspected COPD：COPD-SQ≥16，and no evidence of airflow limitation after bronchodilators\n  * Confirmed COPD：According to the diagnostic criteria in the 2021 Revised Edition of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease and the 2026 GOLD Report, a diagnosis requires the presence of symptoms (such as dyspnea, chronic cough, or sputum production), a history of exposure to risk factors (e.g., smoking, biomass fuels, occupational exposures, or air pollution), evidence of persistent airflow limitation (post-bronchodilator FEV1\u002FFVC \\\u003C 0.70), and the exclusion of alternative diagnoses.\n  * Exclude acute exacerbation within the last month Asthma group：\n  * Age：≥3\n  * Suspected asthma：Patients with chronic respiratory symptoms but no evidence of variable airflow limitation\n  * Confirmed asthma：According to the diagnostic criteria in the 2024 Chinese Guidelines for the Prevention and Treatment of Bronchial Asthma and the 2025 GINA Report, diagnosis requires the presence of recurrent symptoms (such as wheezing, shortness of breath, chest tightness, and cough) that resolve spontaneously or with treatment; evidence of variable airflow limitation (e.g., a positive bronchodilator reversibility test, a positive bronchial provocation test, or an average daily diurnal PEF variability of \\>10% over at least 7 consecutive days); and the exclusion of alternative diagnoses.\n\nHealthy subjects:\n\n* Age ≥ 3 (See Table 1 for details)\n* No respiratory symptoms（cough, expectoration, shortness of breath, wheezing, etc）\n* No history of serious cardiopulmonary or other systemic diseases, especially no history of respiratory diseases and surgery\n* No history of respiratory infection within the past 4 weeks; non-smoker or total lifetime smoking \\\u003C 100 cigarettes\n* No history of occupational exposure to harmful gases or dust, or serious pollution of the work or living environment\n* No abnormalities on chest physical examination\n* No abnormalities were found on chest imaging (X-ray, CT) records within the past year.\n* Body mass index within the normal range (18.5\\~24.9) Confirmed Bronchiectasis Group：\n* Age ≥ 3 years\n* Clinical history consistent with bronchiectasis, confirmed by CT scan\n* No other concurrent or accompanying respiratory diseases at present Confirmed ILD Group：\n* Age ≥ 3 years\n* Fibrotic interstitial lung disease: HRCT scan shows fibrotic lung disease, defined as reticular abnormalities and traction bronchiectasis with or without honeycombing, and the disease extent \\> 10%; or lung tissue biopsy indicates fibrotic interstitial changes\n* No other concurrent or accompanying respiratory diseases at present Confirmed Upper Airway Obstruction Group：\n* Age ≥ 3 years, gender not restricted\n* History of upper airway inflammation, injury, endotracheal intubation or tracheotomy, burns, foreign body aspiration, tracheal tumor, or other conditions that can cause large airway obstruction\n* Clinical manifestations are mainly dyspnea and shortness of breath, which are significantly aggravated after activity, and sometimes symptom exacerbation is related to body position\n* Pulmonary function test shows significant limitation of inspiratory or expiratory flow in the F-V curve, presenting a characteristic plateau pattern\n* At least one of the following evidences: chest CT scan or upper airway three-dimensional reconstruction confirms upper airway stenosis; laryngoscopy or bronchoscopy reveals tracheal\u002Fbronchial wall thickening and\u002For stenosis, intratracheal nodules or neoplasms, tumor infiltration, tracheal mucosal congestion, tracheal cartilage collapse, etc\n\nExclusion Criteria:\n\n* • Contraindications for oscillometry testing and spirometry testing: Oscillometry testing: Severe and intolerable dyspnea, acute exacerbation of respiratory infection, uncontrolled epilepsy, oral or facial diseases or deformities preventing proper latching, tympanic membrane perforation, need for continuous oxygen therapy, indwelling gastric tube, tracheotomy with inability to close the tube, currently undergoing artificial ventilation and unable to temporarily stop the procedure; Spirometry testing: Recent severe cardiovascular disease, epileptic seizures, uncontrolled hypertension, aortic aneurysm, severe hyperthyroidism, heart rate \\>120 bpm, tympanic membrane perforation, other respiratory infectious diseases, etc.;\n\n  * Other respiratory diseases that affect lung function results： such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, etc.; Recent surgical history that affects lung function results, including open-chest surgery, pleural effusion surgery, etc.;\n  * Poor cooperation during basic lung function tests, failing to meet quality control requirements;\n  * Breastfeeding women;\n  * Participants deemed unlikely by the researcher to comply with research procedures and restrictions.",true,"3 Years",{"count":121,"type":23},4000,"1 Day","This is a prospective, multicenter, observational cohort study enrolling approximately 4,000 subjects across about 50 centers, including patients with COPD (confirmed and suspected), asthma (confirmed and suspected), bronchiectasis, interstitial lung disease (ILD), upper airway obstruction (UAO), and healthy controls. Participants will undergo standardized clinical assessments, cough search, FENO, ETCO2, impulse oscillometry, spirometry, and\u002For bronchodilator test, and\u002For bronchoprovocation test, and\u002For diffusion capacity test at a single baseline visit, with no investigational intervention or treatment assignment. The primary objective is to evaluate the diagnostic performance of portable impulse oscillometry in Chronic respiratory diseases and to develop an artificial intelligence diagnostic model for COPD based on oscillometry. The study duration per subject is limited to the screening\u002Fbaseline visit, with no follow-up visits planned.",[125,126,127,128,129,130],"COPD","Asthma (Diagnosis)","Chronic Respiratory Diseases","Bronchiectasis","Interstitial Lung Disease (ILD)","Upper Airway Obstruction",{"date":107,"type":43},{"date":133,"type":23},"2026-07-30",{"date":135,"type":23},"2027-08-30",{"name":49,"class":50},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":148,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":51},"100638496","multimodal-ai-guided-recovery-management-after-lung-cancer-surgery-100638496","NCT07588737","Multimodal AI-Guided Recovery Management After Lung Cancer Surgery","Multimodal Artificial Intelligence-Guided Symptom Monitoring and Recovery Management After Lung Cancer Surgery: A 20-Center Prospective Randomized Controlled Trial","AI-LungRecover","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Clinically or pathologically diagnosed with lung cancer.\n3. Undergoing lung cancer-related thoracic surgery.\n4. Surgical procedures may include video-assisted thoracoscopic surgery, robot-assisted thoracic surgery, or open thoracic surgery.\n5. Surgical extent may include wedge resection, segmentectomy, lobectomy, sleeve resection, combined resection, bilobectomy, or pneumonectomy.\n6. Clinically stable after surgery and able to participate in symptom assessment and postoperative recovery management.\n7. Able to use a smartphone or study device, or has a caregiver who can assist with use.\n8. Able to complete patient-reported symptom assessments and postoperative recovery information reporting.\n9. Provides written informed consent.\n\nExclusion Criteria:\n\n1. Patients receiving non-surgical treatment only.\n2. Patients undergoing bronchoscopy, percutaneous biopsy, or other non-surgical diagnostic or therapeutic procedures only.\n3. Clinically unstable after surgery and unable to participate in symptom assessment or recovery management.\n4. Requiring prolonged intensive care unit treatment, continuous advanced life support, or continuous intensive medical management.\n5. Severe cognitive impairment, psychiatric disorder, language communication disorder, or other conditions that preclude completion of study assessments.\n6. Unable to use a smartphone or study device and without a caregiver who can assist with use.\n7. Currently participating in another interventional clinical study that may affect the primary outcome of this trial.\n8. Any other condition judged by the investigator to make the patient unsuitable for participation in this study.","80 Years",{"count":147,"type":23},868,[26],"This study is a multicenter, prospective, randomized controlled trial designed to evaluate the effectiveness and safety of a multimodal artificial intelligence (AI)-guided postoperative recovery management system in patients after lung cancer surgery. Eligible patients will be enrolled after surgery when their clinical condition is stable and will be randomly assigned to either an AI-guided recovery management group or a usual postoperative care group.\n\nPatients in the AI-guided group will receive usual postoperative care plus a multimodal AI-based recovery management system. The system will collect patient-reported symptoms, vital signs, physical activity, respiratory rehabilitation information, recovery-related data, and, when needed, wound or chest-related images or short videos. Based on these data, the system will provide recovery feedback, general nursing advice, respiratory rehabilitation reminders, activity guidance, and risk stratification alerts. For red-flag symptoms or high-risk conditions, the system will advise patients to contact the clinical team or seek medical care.\n\nPatients in the usual-care group will receive standard postoperative management after lung cancer surgery and will complete symptom assessments at the same prespecified time points, but they will not receive AI-generated individualized recovery feedback or AI-generated risk alerts.\n\nThe primary outcome is the number of MDASI-LC-derived target symptom threshold events within 30 days after surgery. Target symptoms include pain, fatigue, disturbed sleep, shortness of breath, and cough. Secondary outcomes include overall target symptom burden, quality of recovery, time to recovery to a mild-symptom state, functional interference, respiratory rehabilitation adherence, physical activity adherence, unplanned healthcare utilization, pulmonary complications, and unplanned readmission.",[151,152,153,154],"Postoperative Care","Rehabilitation","Artificial Intelligence (Al)","Randomized Controlled Trial (RCT)",[156,157,158,159],"Artificial Intelligence","Large Language Model","Postoperative Rehabilitation","Thoracic Surgery","2026-05-09",{"date":162,"type":43},"2026-05-15",{"date":164,"type":43},"2025-03-01",{"date":166,"type":23},"2026-12-31",{"name":49,"class":50},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":177,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100633167","phase-2-efficacy-and-safety-of-lifei-qingchang-granules-for-stable-bronchiectasis-100633167","NCT07523165","Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of Lifei Qingchang Granules for Stable Bronchiectasis","Inclusion Criteria:\n\n* Aged 18 to 75 years old, regardless of sex.\n* Diagnosed with bronchiectasis confirmed by High-Resolution Computed Tomography (HRCT) scan.\n* Bronchiectasis is currently in the stable phase.\n* Experienced at least one acute exacerbation of bronchiectasis within the previous 12 months.\n* Diagnosed with the Traditional Chinese Medicine (TCM) syndrome of \"Phlegm-Heat Obstructing the Lungs\".\n* Able to understand the study protocol and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Allergic to any ingredients of the investigational drug or placebo.\n* Comorbid with other severe systemic diseases (e.g., coronary heart disease, stroke, severe hypertension \\[systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg\\], active gastric ulcer, uncontrolled diabetes \\[fasting venous blood glucose ≥ 10 mmol\u002FL\\], malignant tumors, abnormal liver or kidney function \\[AST, ALT, or GGT \\> 2 times the upper limit of normal; or serum creatinine \\> 2 times the upper limit of normal\\]) or psychiatric disorders.\n* Comorbid with asthma, allergic bronchopulmonary aspergillosis (ABPA), or active pulmonary tuberculosis.\n* Comorbid with chronic obstructive pulmonary disease (COPD) and presenting COPD as the primary clinical manifestation (as judged by the investigator).\n* Use of inhaled, oral, or intravenous antibiotics within 4 weeks prior to enrollment.\n* Type 2 respiratory failure requiring long-term non-invasive mechanical ventilation or oxygen therapy (\\> 10 hours\u002Fday).\n* History of drug abuse, psychotropic drug dependence, or alcohol abuse.\n* Current smokers or those unable to stop smoking during the study.\n* Pregnant or lactating women, planning to become pregnant during the study, or refusing to use reliable contraceptive methods throughout the study period.\n* Participation in any other clinical trials within 3 months prior to enrollment.\n* Considered unsuitable for participation in this clinical study by the investigator.",{"count":176,"type":23},150,[178],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of Lifei Qingchang Granules in the treatment of patients with stable bronchiectasis. This is a multicenter, randomized, double-blind, placebo-controlled clinical trial.\n\nResearchers plan to enroll a total of 150 adult participants (aged 18-75) who have been diagnosed with stable bronchiectasis and experience at least one acute exacerbation in the past 12 months. Participants will be randomly assigned into two groups in a 1:1 ratio:\n\n* The treatment group will receive Lifei Qingchang Granules along with standard postural drainage therapy.\n* The control group will receive a matching placebo along with standard postural drainage therapy.\n\nThe treatment period will last for 3 months. The main goal is to see if the treatment can improve patients' respiratory symptoms and overall quality of life.",[128],[182,183,184,185,186],"Stable Bronchiectasis","Traditional Chinese Medicine","Phlegm-Heat Syndrome","Lifei Qingchang Granules","Postural Drainage","2026-04-04",{"date":189,"type":43},"2026-04-13",{"date":191,"type":23},"2026-04",{"date":193,"type":23},"2028-04",{"name":49,"class":50},3,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":203,"targetDuration":4,"studyType":24,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":51},"100624770","phase-2-limertinib-plus-radiotherapy-for-egfr-mutant-nsclc-with-brain-metastases-100624770","NCT07413952","Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases","Efficacy and Safety of Limertinib (ASK120067) Combined With Radiotherapy as First-Line Treatment in Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases: A Single-Arm, Multicenter, Prospective Phase II Study","Inclusion Criteria:\n\nPatients must voluntarily agree to participate in this study and sign a written informed consent form.\n\nPatients aged 18-75 years. Patients must have histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC), staged as IV according to the 9th edition of the American Joint Committee on Cancer (AJCC) TNM staging system.\n\nHistological or cytological reports issued by nationally accredited hospitals or third-party testing institutions confirming the presence of EGFR classical mutations (19Del \\& 21L858R).\n\nECOG PS score of 0-1, and an estimated survival of ≥3 months, as determined by the investigator.\n\nBrain metastases (meningeal\u002Fparenchymal) confirmed by CT or MRI, with or without symptoms.\n\nPatients must have at least one measurable lesion according to RECIST 1.1 criteria.\n\n≥3 primary brain lesions, with at least one lesion ≥2 cm. Patients must not have received any prior systemic anti-cancer treatment for advanced\u002Fmetastatic non-small cell lung cancer, including standard chemotherapy, biological therapy, targeted therapy, immunotherapy, or investigational drug therapy. Patients who have received adjuvant or neoadjuvant therapy (chemotherapy and\u002For radiotherapy) are eligible if no disease progression occurred within 6 months after completion of treatment. Patients who have received local treatment (radiotherapy or pleural perfusion therapy) are also eligible if the treated lesions are not target lesions.\n\nPatients must meet the following organ function criteria:\n\nAbsolute neutrophil count (ANC) ≥1.5×10⁹\u002FL. 2) Platelet count ≥100×10⁹\u002FL. 3) Hemoglobin (HGB) ≥90 g\u002FL. 4) Serum total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN). For patients with liver metastases, TBIL may be up to 3× ULN.\n\n5\\) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN. For patients with liver metastases, AST and ALT may be up to 5× ULN.\n\n6\\) Serum creatinine (SCr) ≤1.5× ULN, or creatinine clearance ≥50 mL\u002Fmin (calculated using the Cockcroft-Gault formula).\n\nMale patients with reproductive potential and female patients who may become pregnant must use highly effective contraceptive methods during the study and for 12 months after treatment discontinuation.\n\nExclusion Criteria:\n\nPatients unable to confirm a diagnosis of non-small cell lung cancer (NSCLC) through histological or cytological examination.\n\nPatients expected to require other systemic anti-cancer treatments outside of this study during the trial period.\n\nPatients diagnosed with malignant tumors within the past 2 years, except for well-controlled cutaneous basal cell carcinoma, cervical carcinoma in situ, or ductal carcinoma in situ of the breast.\n\nPatients with significant gastrointestinal diseases that may affect drug intake or absorption, including but not limited to peptic ulcer disease or inflammatory bowel disease.\n\nPatients with known or suspected hypersensitivity to the study interventions (lielitinib and radiotherapy) or components of study-related preparations.\n\nPatients who have previously received any epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy.\n\nPatients who have used strong CYP3A4 inhibitors or inducers within 7 days prior to the first dose of study drug, or who are expected to require long-term use of these medications during the trial. Additionally, patients who have used traditional Chinese medicine or preparations with anti-tumor indications within 2 weeks prior to the first dose of study drug, or who are expected to require such use during the trial, will also be excluded.\n\nPatients with a history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring corticosteroid treatment. Patients with acute exacerbation or progressive pulmonary symptoms at baseline, or those considered unsuitable for inclusion by the investigator due to high-risk factors for interstitial lung disease, will also be excluded.\n\nPatients with significant arrhythmia (e.g., QT interval \\>470 ms) or heart failure (left ventricular ejection fraction \\\u003C50%).\n\nPregnant or lactating women. Patients currently participating in or who have participated in other clinical trials within the past 4 weeks.\n\nPatients with serious acute or chronic medical or psychiatric conditions, as determined by the investigator, that may increase the risks associated with study participation or interfere with the interpretation of study results.",{"count":204,"type":23},45,[178],"Patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge. Although EGFR-TKIs have demonstrated intracranial activity, disease control is still suboptimal in some patients.\n\nLimertinib (ASK120067) is a novel third-generation EGFR tyrosine kinase inhibitor with favorable central nervous system penetration and encouraging intracranial antitumor activity. The potential synergistic effect of limertinib combined with radiotherapy warrants further investigation.\n\nThis prospective, multicenter, single-arm phase II study aims to evaluate the efficacy and safety of first-line limertinib combined with radiotherapy in this patient population.",[208],"NSCLC","2026-02-10",{"date":211,"type":43},"2026-02-17",{"date":213,"type":23},"2026-04-01",{"date":215,"type":23},"2029-12-31",{"name":49,"class":50},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":24,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":51},"100623340","hybrid-robot-assisted-percutaneous-ablation-and-non-intubated-vats-for-multiple-pulmonary-nodules-100623340","NCT07395362","Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules","A Prospective Single-Arm Study Evaluating the Safety, Feasibility, and Perioperative Recovery of Robot-Assisted Percutaneous Ablation\u002FLocalization Combined With Non-Intubated Video-Assisted Thoracoscopic Surgery for Multiple Pulmonary Nodules","Inclusion Criteria:\n\n1. Age 18 to 85 years at the time of enrollment.\n2. Presence of multiple pulmonary nodules identified on chest computed tomography (CT).\n3. At least one dominant pulmonary lesion meeting standard indications for thoracoscopic surgical resection based on radiologic assessment.\n4. At least one additional pulmonary nodule for which complete surgical resection is considered undesirable due to lung parenchyma preservation concerns or procedural risk, and deemed suitable for robot-assisted CT-guided percutaneous intervention.\n5. Determined by a multidisciplinary team (MDT) to be an appropriate candidate for the predefined hybrid treatment strategy.\n6. Eligible for non-intubated video-assisted thoracoscopic surgery based on preoperative anesthetic evaluation (ASA physical status I-III).\n7. Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Pulmonary nodules located centrally or adjacent to major airways, major vessels, or the heart, where safe percutaneous intervention is not feasible.\n2. Pure ground-glass nodules with a maximum diameter \\\u003C 6 mm, for which active surveillance is recommended.\n3. Clinical evidence of N1\u002FN2 lymph node involvement or distant metastasis.\n4. Severe cardiopulmonary disease, interstitial lung disease, or other conditions that preclude thoracoscopic surgery or anesthesia.\n5. Coagulation disorders or ongoing anticoagulation therapy that cannot be safely discontinued.\n6. Pregnancy or breastfeeding.\n7. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study assessments.","85 Years",{"count":226,"type":23},30,[26],"The goal of this clinical trial is to evaluate the safety and feasibility of a predefined hybrid treatment strategy in patients with multiple pulmonary nodules who require surgical management of at least one dominant lesion. The strategy combines robot-assisted CT-guided percutaneous ablation and\u002For localization with non-intubated video-assisted thoracoscopic surgery (NiVATS) performed during the same hospitalization.\n\nThe main questions this study aims to answer are:\n\nIs the hybrid treatment strategy associated with an acceptable rate of perioperative serious complications?\n\nCan the planned combination of robot-assisted percutaneous intervention and NiVATS be completed successfully in a real-world clinical setting?\n\nParticipants will:\n\nUndergo preoperative evaluation and multidisciplinary assessment;\n\nReceive robot-assisted CT-guided percutaneous ablation and\u002For localization for selected pulmonary nodules;\n\nUndergo non-intubated video-assisted thoracoscopic surgery for resection of the dominant pulmonary lesion;\n\nBe followed for perioperative outcomes and short-term recovery up to 30 days after surgery.",[65],[231,232,233,234,235],"Multiple pulmonary nodules","Ground-glass nodules","Robot-assisted percutaneous ablation","CT-guided intervention","Non-intubated video-assisted thoracoscopic surgery NiVATS","2026-02-06",{"date":238,"type":43},"2026-02-09",{"date":240,"type":23},"2026-02-28",{"date":242,"type":23},"2026-10-01",{"name":49,"class":50},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":251,"targetDuration":4,"studyType":24,"phases":253,"briefSummary":254,"conditions":255,"keywords":260,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":51},"100624399","tubeless-strategy-for-enhanced-recovery-after-sublobar-resection-100624399","NCT07409129","Tubeless Strategy for Enhanced Recovery After Sublobar Resection","Tubeless Strategy Within an Enhanced Recovery After Surgery (ERAS) Protocol for Thoracoscopic Sublobar Resection: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Scheduled for uniportal or multiportal video-assisted thoracoscopic surgery (VATS) for sublobar resection (wedge or segmentectomy).\n* Presence of peripheral lung nodules ≤ 2 cm in diameter and ≤ 2 cm from the pleura, confirmed by CT scan.\n* Ability to understand and provide written informed consent.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n\nExclusion Criteria:\n\n* Severe pleural adhesions or fibrosis that would preclude non-intubated anesthesia or tubeless approach.\n* Severe cardiopulmonary dysfunction: FEV1 \\\u003C 50% predicted, DLCO \\\u003C 60% predicted, heart failure (NYHA class III-IV), or unstable angina.\n* Pregnancy or lactation (confirmed by urine test if applicable).\n* Inability to tolerate one-lung ventilation due to anatomical or physiological reasons.\n* History of ipsilateral thoracic surgery.\n* Active pulmonary infection, uncontrolled diabetes, or other comorbidities that increase surgical risk.\n* Participation in another interventional trial within 30 days.",{"count":252,"type":23},138,[26],"This is a prospective, randomized controlled clinical trial conducted at a single center. The study aims to evaluate whether a \"tubeless\" strategy can enhance recovery for patients undergoing minimally invasive thoracoscopic sublobar resection (wedge or segment resection) for small lung nodules.\n\nParticipants will be randomly assigned to one of two groups:\n\n* The experimental group will receive the \"tubeless\" strategy, which includes non-endotracheal intubation anesthesia (using a laryngeal mask) and no routine chest tube drainage after surgery.\n* The control group will receive the traditional strategy, which includes double-lumen endotracheal intubation anesthesia and routine chest tube drainage.\n\nThe main goal is to compare the rate of achieving high-quality fast-track recovery at 24 hours after surgery between the two groups. This study will provide evidence on whether the tubeless approach can help patients recover faster and more comfortably without compromising safety.",[256,257,258,259],"Pulmonary Nodules","Early Stage Lung Cancer (I and II)","Thoracoscopic Surgery","Sublobar Resection",[261,262,263,264,265,266],"Tubeless Surgery","Non-intubated Anesthesia","Enhanced Recovery After Surgery","Sublobar resection","Wedge Resection","Segmentectomy",{"date":268,"type":43},"2026-02-13",{"date":270,"type":23},"2026-02-01",{"date":272,"type":23},"2026-09-01",{"name":49,"class":50},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":145,"enrollmentInfo":282,"targetDuration":4,"studyType":24,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":51},"100623341","non-intubated-versus-intubated-anesthesia-for-thoracoscopic-sublobar-resection-100623341","NCT07395375","Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection","A Multicenter, Randomized, Controlled Trial of Non-Intubated Spontaneous Breathing Anesthesia Versus Intubated Mechanical Ventilation Anesthesia in Thoracoscopic Sublobar Resection: A Stratified Analysis Study Focusing on Safety and Recovery Quality","NIVA-TSLR","Inclusion Criteria:\n\n1. Aged 18 to 80 years (inclusive).\n2. Scheduled for elective, uniportal or single utility port video-assisted thoracoscopic sublobar resection (wedge resection or simple anatomical segmentectomy).\n3. Preoperative CT diagnosis of a peripheral pulmonary nodule meeting: maximum diameter ≤ 2.0 cm and outer edge ≤ 2.0 cm from the visceral pleura.\n4. American Society of Anesthesiologists (ASA) physical status I or II.\n5. Preoperative pulmonary function: FEV1% ≥ 60% of predicted.\n6. Preoperative arterial blood gas analysis (room air): PaO₂ ≥ 80 mmHg and PaCO₂ ≤ 45 mmHg.\n7. Body Mass Index (BMI) between 18.0 and 28.0 kg\u002Fm².\n8. Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Cardiovascular: NYHA class ≥ III, unstable angina, acute myocardial infarction within 3 months, or severe arrhythmia requiring medication.\n2. Respiratory: Severe COPD (GOLD 3 or 4), symptomatic interstitial lung disease, resting SpO₂ \\\u003C 92% on room air, or severe pulmonary hypertension (estimated systolic PAP \\> 50 mmHg).\n3. Airway Risk: Modified Mallampati score ≥ 3, mouth opening \\\u003C 3 cm, or other predictors of difficult airway management.\n4. Radiological: Preoperative CT suggesting extensive pleural adhesion, moderate or large pleural effusion, or mediastinal lymph nodes \\> 1.5 cm short axis.\n5. Contraindications to Regional Anesthesia: Infection\u002Ftumor at the block site, patient refusal, or allergy to local anesthetics.\n6. Coagulopathy: Platelet count \\\u003C 100×10⁹\u002FL, INR \\> 1.5, or use of anticoagulants that cannot be safely discontinued perioperatively.\n7. Other: Severe hepatic or renal dysfunction, previous ipsilateral thoracic surgery, pregnancy or lactation, active psychiatric or cognitive disorders, or participation in another conflicting clinical trial.",{"count":283,"type":23},1600,[26],"This is a large clinical study that compares two different types of anesthesia for patients undergoing a specific kind of minimally invasive lung surgery (thoracoscopic sublobar resection) to remove small, early-stage lung nodules.\n\nThe study aims to find out if a newer anesthesia method, known as \"non-intubated anesthesia\" (where patients breathe on their own with the help of a laryngeal mask airway and nerve blocks for pain control), is as safe as the traditional \"intubated anesthesia\" (which uses a breathing tube and a machine to breathe for the patient).\n\nThe main goals of the study are, in order:\n\n1. Safety First: To confirm that the non-intubated method does not lead to more lung complications within 30 days after surgery compared to the traditional method.\n2. Effectiveness: If it is proven safe, the study will then check if patients receiving the non-intubated anesthesia have a better quality of recovery in the first 24 hours after surgery (e.g., less pain, fewer side effects like a sore throat, and a faster return to normal activities).\n\nApproximately 1600 patients from multiple hospitals will be randomly assigned (like flipping a coin) to receive one of the two anesthesia methods. Neither the patients nor the surgeons will be told which group the patient is in when assessing the main outcomes after surgery, to ensure the results are fair and unbiased.\n\nThe results of this study will provide high-quality evidence to help doctors and patients choose the best and most comfortable anesthesia option for this type of lung surgery.",[256,287,159],"Lung Neoplasms",[289,290,291,263,38],"Non-intubated Thoracic Surgery","Lung Sublobar Resection","Video-Assisted Thoracoscopic Surgery",{"date":238,"type":43},{"date":294,"type":23},"2026-03-01",{"date":296,"type":23},"2027-08-01",{"name":49,"class":50},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":145,"enrollmentInfo":305,"targetDuration":4,"studyType":24,"phases":307,"briefSummary":308,"conditions":309,"keywords":313,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":322,"leadSponsor":323,"locationsCount":51},"100623339","safety-and-recovery-of-tubeless-strategy-in-uniportal-vats-wedge-resection-100623339","NCT07395349","Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection","Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection: A Single-Center, Prospective Randomized Controlled Study Based On Different Intraoperative Pleural Space Management Strategies","Inclusion Criteria:\n\n1. Age 18 to 80 years\n2. Scheduled to undergo uniportal video-assisted thoracoscopic (VATS) wedge resection\n3. Able to tolerate general anesthesia and single-lung ventilation\n4. Passed a standardized intraoperative water-seal air leak test, confirming absence of persistent air leak before chest closure\n5. Able and willing to provide written informed consent\n6. Able to complete postoperative assessments and 30-day follow-up\n\nExclusion Criteria:\n\n1. Planned anatomical lung resection (segmentectomy or lobectomy) or combined complex thoracic procedures\n2. Extensive pleural adhesions, severe emphysema, bullous lung disease, or other conditions associated with high risk of air leak\n3. Positive intraoperative air leak test indicating persistent air leak\n4. Requirement for additional intraoperative procedures that may significantly affect pleural air leak or lung re-expansion\n5. Conversion to multiport VATS or thoracotomy before randomization\n6. Severe comorbidities or other conditions deemed by the investigators to make participation inappropriate\n7. Inability to complete follow-up or insufficient clinical data",{"count":306,"type":23},300,[26],"Brief Summary\n\nThe goal of this clinical trial is to evaluate the safety and recovery outcomes of different tubeless strategies in adult patients undergoing uniportal video-assisted thoracoscopic (VATS) wedge resection who are confirmed to have no persistent air leak intraoperatively.\n\nThe main questions it aims to answer are:\n\nDoes double intraoperative aspiration tubeless strategy reduce the rate of postoperative pleural re-intervention within 30 days compared with single intraoperative aspiration tubeless strategy?\n\nDo different intraoperative pleural space management strategies affect early postoperative recovery quality and pain?\n\nIf there is a comparison group:\n\nResearchers will compare conventional chest tube drainage, single intraoperative aspiration tubeless, and double intraoperative aspiration tubeless strategies to determine their effects on postoperative pleural re-intervention and recovery outcomes.\n\nParticipants will:\n\nUndergo uniportal VATS wedge resection\n\nReceive a standardized intraoperative air leak test before chest closure\n\nBe randomly assigned intraoperatively to one of three pleural space management strategies\n\nComplete postoperative assessments including chest imaging, pain evaluation, and recovery quality questionnaires\n\nBe followed for 30 days after surgery for safety outcomes",[310,311,312],"Pulmonary Nodule","Pneumothorax","Postoperative Complications",[314,265,315,316,317,318,319],"Uniportal VATS","Tubeless","Intraoperative Aspiration","Chest Tube Drainage","Enhanced Recovery After Surgery (ERAS)","Lung Re-expansion",{"date":238,"type":43},{"date":240,"type":23},{"date":242,"type":23},{"name":49,"class":50},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":334,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100622511","perioperative-recovery-outcomes-with-a-spontaneous-breathing-strategy-in-severely-underweight-lung-transplant-recipients-100622511","NCT07384572","Perioperative Recovery Outcomes With a Spontaneous Breathing Strategy in Severely Underweight Lung Transplant Recipients","Evaluation of Perioperative Recovery Outcomes of a Spontaneous Breathing-Preserving Strategy in Severely Underweight Lung Transplantation: A Prospective, Multicenter, Single-Arm Clinical Study","\\[1\\] Inclusion Criteria\n\n1. Age and informed consent: Age ≥18 years; able to understand the study and provide written informed consent; willing and able to comply with follow-up.\n2. Transplant candidacy: Listed in CLuTR or the participating center's lung transplant waiting list and scheduled to undergo allogeneic lung transplantation.\n3. Low body weight definition (core cohort criterion): Preoperative BMI \\\u003C16 kg\u002Fm², calculated using the most recent traceable preoperative height and weight within the evaluation window.\n4. Preoperative support status: Not receiving ongoing invasive mechanical ventilation (endotracheal intubation or tracheostomy) and not on ECMO or other extracorporeal life support preoperatively.\n5. Minimum acceptable end-organ function: LVEF ≥40%; eGFR ≥40 mL\u002Fmin\u002F1.73 m²; no evidence of acute liver failure or decompensated cirrhosis\u002Fportal hypertension; American Society of Anesthesiologists (ASA) physical status ≤ IV.\n6. Infection and transmissible diseases: No evidence of active infection; no active tuberculosis; HIV\u002FHBV\u002FHCV status meeting center transplant requirements (e.g., undetectable viral load, where applicable).\n7. Rehabilitation and support: Demonstrated potential for postoperative rehabilitation (able to participate in training) and reliable caregiving support (at least one primary caregiver).\n\n\\[2\\] Exclusion Criteria\n\n1. Consent\u002Fcompliance: Refusal or withdrawal of informed consent; investigator judgment that follow-up cannot be completed or presence of recurrent severe non-adherence.\n2. Transplant type: Retransplantation, multi-organ transplantation, or planned lobar lung transplantation.\n3. Recent major cardiovascular\u002Fcerebrovascular events: Acute coronary syndrome\u002Fmyocardial infarction or stroke within the past 30 days.\n4. Severe organ dysfunction\u002Facute failure: LVEF \\\u003C40%; eGFR \\\u003C40 mL\u002Fmin\u002F1.73 m²; acute liver failure or decompensated cirrhosis\u002Fportal hypertension; acute renal failure requiring dialysis with low likelihood of recovery; significant preoperative neuropsychiatric disorder or altered mental status.\n5. High-risk\u002Fsevere infection: Septic shock; active extrapulmonary or disseminated infection; active tuberculosis; detectable HIV viral load (or otherwise not meeting center transplant standards).\n6. High bleeding risk: Severe bronchiectasis not treated with preoperative vascular intervention or not readily correctable.\n7. Malignancy: Active malignancy or malignancy with high risk of recurrence or cancer-related mortality.\n8. Severe chest wall or spinal deformity: Definitively diagnosed severe thoracic cage deformity or spinal deformity.\n9. Substance use\u002Fdependence: Current use of cigarettes, e-cigarettes, inhaled cannabis, or intravenous drugs.\n10. Tubeless\u002Fspontaneous breathing-preserving strategy not safely feasible: Determined by the anesthesia team to have a difficult airway or unsafe supraglottic\u002Fnon-intubated airway management (e.g., anticipated intraoperative airway difficulty, pharyngeal\u002Flaryngeal narrowing not suitable for a laryngeal mask airway), including but not limited to: Mallampati class \\>III, mouth opening \\\u003C3 cm, thyromental distance \\\u003C5 cm, or significant airway anatomic variants (e.g., aberrant right upper lobe bronchial takeoff in a planned right lung transplant) deemed difficult to manage safely with an LMA or single-lumen tube.\n11. Donor\u002Fdonor lung limitations: Donor age \\>60 years; donor mechanical ventilation \\>14 days; positive donor airway microbiology deemed unacceptable by the transplant team.\n12. Protected populations: Pregnant or breastfeeding women.","74 Years",{"count":333,"type":23},56,[26],"The goal of this prospective, multicenter, single-arm clinical study is to learn whether a spontaneous breathing-preserving perioperative management strategy can improve recovery and is safe in lung transplant recipients with very low body weight (body mass index \\[BMI\\] \\\u003C16 kg\u002Fm²).\n\nThe main questions it aims to answer are whether, in lung transplant recipients with very low body weight (BMI \\\u003C16 kg\u002Fm²), a spontaneous breathing-preserving anesthesia-surgical strategy combined with standardized nutritional optimization and a prehabilitation program can improve early postoperative recovery and perioperative survival. Specifically, the study will assess the proportion of participants who require postoperative invasive mechanical ventilation, postoperative length of hospital stay, and perioperative survival within the protocol-defined time window (e.g., through hospital discharge).\n\nParticipants will undergo lung transplantation using a perioperative strategy that preserves spontaneous breathing whenever clinically appropriate, with predefined criteria for conversion to endotracheal intubation and mechanical ventilation if needed. They will receive standard postoperative monitoring and supportive care, with respiratory support events and perioperative complications assessed during the index hospitalization (and up to 30 days after surgery, if specified in the protocol). Key outcomes will be collected from routine clinical care, including postoperative ventilatory support status, length of hospital stay, and major safety events.",[337],"End-stage Lung Disease",[339,263,340],"Lung transplantation","Severely Underweight","2026-01-31",{"date":343,"type":43},"2026-02-03",{"date":345,"type":23},"2026-01-13",{"date":347,"type":23},"2029-01-30",{"name":49,"class":50},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":118,"sex":18,"minAge":19,"maxAge":331,"enrollmentInfo":356,"targetDuration":4,"studyType":24,"phases":358,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":4},"100622508","perioperative-recovery-outcomes-of-a-spontaneous-breathing-preserving-strategy-in-salvage-lung-transplantation-100622508","NCT07384533","Perioperative Recovery Outcomes of a Spontaneous Breathing-Preserving Strategy in Salvage Lung Transplantation","Perioperative Recovery Outcomes of a Spontaneous Breathing-Preserving Strategy in Salvage Lung Transplantation: A Prospective Multicenter Single-Arm Clinical Study","\\[1\\] Inclusion Criteria\n\n1. Age and informed consent: Age ≥18 years. The participant or their legally authorized representative (LAR) is able to complete the informed consent process in a rescue\u002Femergent transplant setting and sign written informed consent.\n2. Transplant candidacy: Listed in the China Lung Transplantation Registry (CLuTR) or the lung transplant waiting list of the participating center, with a planned allogeneic lung transplantation.\n3. Rescue\u002Fbridge definition (core cohort criterion): Meets any of the following conditions and is deemed by the study team to require rescue\u002Femergent transplantation and to proceed to transplant: continuous invasive mechanical ventilation preoperatively (endotracheal intubation or tracheostomy); or preoperative extracorporeal membrane oxygenation (ECMO) \u002F other extracorporeal life support (ECLS); or urgent escalation of support due to progressive respiratory and\u002For circulatory failure, entering a rescue transplant pathway.\n4. Minimum key organ function: Left ventricular ejection fraction (LVEF) ≥40%; estimated glomerular filtration rate (eGFR) ≥40 mL\u002Fmin\u002F1.73 m²; no evidence of acute liver failure or decompensated cirrhosis\u002Fportal hypertension; American Society of Anesthesiologists (ASA) Physical Status classification ≤ IV.\n5. Infection and transmissible diseases: No evidence of active infection; no active tuberculosis; HIV\u002FHBV\u002FHCV meet the center's transplant requirements (e.g., undetectable viral load, as applicable).\n6. Rehabilitation and support: Demonstrated potential for postoperative rehabilitation (able to cooperate with training) and reliable caregiving support (at least one primary caregiver).\n\n\\[2\\] Exclusion Criteria\n\n1. Informed consent\u002Fadherence: Refusal of or withdrawal of informed consent; investigator judgment that follow-up cannot be completed or that there is repeated serious non-adherence.\n2. Transplant type: Re-transplantation, multi-organ transplantation, or planned lobar lung transplantation.\n3. Recent major cardiovascular\u002Fcerebrovascular events: Acute coronary syndrome\u002Fmyocardial infarction or stroke within the past 30 days.\n4. Severe organ dysfunction\u002Facute failure: LVEF \\\u003C40%; eGFR \\\u003C40 mL\u002Fmin\u002F1.73 m²; acute liver failure or decompensated cirrhosis\u002Fportal hypertension; acute renal failure requiring dialysis with low likelihood of recovery; significant preoperative neuropsychiatric disorder or impaired consciousness.\n5. High risk of severe infection: Septic shock; active extrapulmonary\u002Fdisseminated infection; active tuberculosis; detectable HIV viral load (or otherwise not meeting the center's transplant criteria).\n6. High risk of major bleeding: Severe bronchiectasis not treated with preoperative vascular intervention or not readily correctable.\n7. Malignancy: Active malignancy or malignancy with high risk of recurrence or cancer-related mortality.\n8. Severe chest wall or spinal deformity: Deemed by the study team to compromise surgical exposure, ventilation\u002Fairway management, or perioperative safety.\n9. Substance use\u002Fdependence: Current smoking, e-cigarette\u002Fvaping use, inhaled cannabis use, or intravenous drug use.\n10. Tubeless\u002Fbreathing-preserved strategy not safely feasible: The anesthesia team judges a difficult airway or laryngeal mask\u002Fnon-intubated airway management to be unsafe (e.g., anticipated difficult airway, pharyngeal\u002Flaryngeal stenosis unsuitable for laryngeal mask, or other conditions unfavorable for airway management), including but not limited to: Mallampati class \\>III, mouth opening \\\u003C3 cm, thyromental distance \\\u003C5 cm, or significant airway anatomical variation (e.g., anomalous right upper lobe bronchial origin in a planned right lung transplantation) such that safe management with a laryngeal mask or single-lumen tube is deemed unlikely.\n11. Donor\u002Fdonor lung limitations: Donor age \\>60 years; donor mechanical ventilation \\>14 days; positive donor airway microbiology that the transplant team deems unacceptable.\n12. Protected population: Pregnant or breastfeeding women.",{"count":357,"type":23},40,[26],"The goal of this prospective, multicenter, single-arm clinical study is to learn whether a breathing-preserved anesthesia-surgical strategy can improve early recovery and perioperative survival in adults undergoing rescue\u002Fbridge lung transplantation.\n\nThe main questions it aims to answer are whether, in adult rescue lung transplant recipients, a breathing-preserved anesthesia-surgical strategy can improve early postoperative recovery and perioperative survival, with a focus on the need for postoperative invasive mechanical ventilation, postoperative length of hospital stay, and perioperative survival outcomes.\n\nParticipants will undergo lung transplantation using a standardized breathing-preserved anesthesia-surgical pathway, with predefined criteria for conversion to endotracheal intubation and\u002For initiation or escalation of extracorporeal support when clinically necessary. Participants will receive standardized perioperative care per each participating center's transplant pathways and will be followed from screening through hospital discharge and up to 30 days after surgery. Routine perioperative data and key postoperative outcomes, including major complications (e.g., graft dysfunction, respiratory support events, infections, bleeding requiring re-intervention, acute kidney injury, rejection, and thrombotic events), will be collected.",[337],[339,263],{"date":343,"type":43},{"date":364,"type":23},"2026-01-30",{"date":366,"type":23},"2028-03-30",{"name":49,"class":50},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":24,"phases":377,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":383,"leadSponsor":384,"locationsCount":4},"100622506","perioperative-recovery-outcomes-with-a-spontaneous-breathing-strategy-in-older-lung-transplant-recipients-100622506","NCT07384507","Perioperative Recovery Outcomes With a Spontaneous Breathing Strategy in Older Lung Transplant Recipients","Evaluation of Perioperative Recovery With a Spontaneous Breathing-Preserving Strategy in Older Lung Transplant Recipients: A Prospective Multicenter Single-Arm Cohort Study","\\[1\\] Inclusion Criteria\n\n1. Age and informed consent: Age ≥70 years; able to understand the study and provide written informed consent, or, where permitted by ethics and applicable regulations, consent may be provided by a legally authorized representative (LAR)\u002Fauthorized surrogate; willing and able to complete follow-up.\n2. Transplant candidacy: Listed in CLuTR or the lung transplant waiting list of the participating center, with a plan to undergo allogeneic lung transplantation.\n3. Preoperative support status: Not receiving ongoing invasive mechanical ventilation (endotracheal intubation or tracheostomy) preoperatively, and not receiving ECMO or other extracorporeal life support.\n4. Minimum key organ function: LVEF ≥40%; eGFR ≥40 mL\u002Fmin\u002F1.73 m²; no evidence of acute liver failure or decompensated cirrhosis\u002Fportal hypertension; ASA physical status ≤ IV (American Society of Anesthesiologists classification).\n5. Infection and communicable diseases: No evidence of active infection; no active tuberculosis; HIV\u002FHBV\u002FHCV status meets the center's transplant requirements (e.g., undetectable viral load, as applicable).\n6. Rehabilitation and support: Demonstrated potential for postoperative rehabilitation (able to participate in training) and reliable caregiving support (at least one primary caregiver).\n\n\\[2\\] Exclusion Criteria\n\n1. Informed consent\u002Fadherence: Refusal or withdrawal of informed consent; investigator judgment that follow-up cannot be completed or there is recurrent severe non-adherence.\n2. Transplant type: Re-transplantation, multi-organ transplantation, or planned lobar lung transplantation.\n3. Recent major cardio-cerebrovascular events: Acute coronary syndrome\u002Fmyocardial infarction or stroke within the past 30 days.\n4. Severe organ dysfunction\u002Facute failure: LVEF \\\u003C40%; eGFR \\\u003C40 mL\u002Fmin\u002F1.73 m²; acute liver failure or decompensated cirrhosis\u002Fportal hypertension; acute renal failure requiring dialysis with low likelihood of recovery; significant preoperative neuropsychiatric disorders or altered consciousness.\n5. High risk of severe infection: Septic shock; active extrapulmonary\u002Fdisseminated infection; active tuberculosis; detectable HIV viral load (or otherwise not meeting the center's transplant criteria).\n6. High bleeding risk: Severe bronchiectasis without preoperative vascular intervention or not correctable\u002Fmitigable.\n7. Malignancy: Active malignancy or tumors with high risk of recurrence or high cancer-related mortality risk.\n8. Extreme body habitus\u002Fmajor deformity: BMI ≥35 kg\u002Fm² or BMI \\\u003C16 kg\u002Fm²; clearly diagnosed severe chest wall deformity or spinal deformity.\n9. Substance use\u002Fdependence: Current use of cigarettes, e-cigarettes, smoked\u002Fvaped cannabis, or intravenous drug use.\n10. Tubeless\u002Fspontaneous-breathing strategy not safely feasible: Deemed by the anesthesia team to have a difficult airway or unsafe supraglottic\u002Fnon-intubated airway management (e.g., anticipated intraoperative airway difficulty, pharyngeal\u002Flaryngeal stenosis not suitable for a laryngeal mask), including but not limited to: Mallampati class \\>III, mouth opening \\\u003C3 cm, thyromental distance \\\u003C5 cm, or significant airway anatomical variations (e.g., aberrant right upper lobe bronchial takeoff with planned right lung transplantation) where safe management with LMA\u002Fsingle-lumen approaches is judged unlikely.\n11. Donor\u002Fdonor lung limitations: Donor age \\>60 years; donor mechanical ventilation \\>14 days; positive donor airway microbiology considered unacceptable by the transplant team.\n12. Protected populations: Pregnant or breastfeeding women.",{"count":376,"type":23},60,[26],"The goal of this prospective, multicenter, single-arm cohort study is to learn whether a lung transplantation approach that preserves patients' spontaneous breathing during surgery can improve early recovery in adults aged 70 years and older undergoing allogeneic lung transplantation.\n\nThe main questions it aims to answer are whether, in adult lung transplant recipients aged 70 years and older, an anesthesia-surgical strategy designed to preserve spontaneous breathing is associated with better early postoperative recovery, specifically in terms of the need for postoperative invasive mechanical ventilation, postoperative length of hospital stay, and perioperative survival.\n\nParticipants will undergo lung transplantation using a standardized anesthesia-surgical strategy intended to preserve spontaneous breathing, with predefined criteria for conversion to tracheal intubation and\u002For ECMO if clinically needed. They will receive standardized perioperative management and routine postoperative care (including ICU monitoring, rehabilitation, and recovery support) as determined by the transplant team. Participants will be assessed throughout hospitalization and followed for postoperative complications and outcomes through discharge and up to 30 days after surgery.",[337],[339,263],{"date":343,"type":43},{"date":364,"type":23},{"date":347,"type":23},{"name":49,"class":50},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":331,"enrollmentInfo":393,"targetDuration":4,"studyType":24,"phases":395,"briefSummary":396,"conditions":397,"keywords":398,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":4},"100622509","breathe-study-spontaneous-breathing-preserved-anesthesia-and-surgical-strategy-for-hospital-recovery-in-lung-transplantation-100622509","NCT07384546","BREATHE Study: Spontaneous Breathing-Preserved Anesthesia and Surgical Strategy for Hospital Recovery in Lung Transplantation","Spontaneous Breathing-Preserved Anesthesia and Surgical Strategy to Improve Early Postoperative Hospital Recovery After Lung Transplantation (BREATHE), A Prospective, Multicenter, Blinded Endpoint Assessment Single-arm Clinical Study","BREATHE-LTx","【1】Inclusion Criteria\n\n1. Age and informed consent: Aged 18-70 years; able to understand the study and provide written informed consent; willing and able to complete follow-up.\n2. Transplant candidacy: Listed in the CLuTR registry and\u002For the local center's lung transplant waiting list, and scheduled to undergo allogeneic lung transplantation.\n3. Preoperative support status: Not on ongoing invasive mechanical ventilation preoperatively (endotracheal intubation or tracheostomy), and not receiving ECMO or other extracorporeal life support.\n4. Minimum key organ function requirements: LVEF ≥40%; eGFR ≥40 mL\u002Fmin\u002F1.73 m²; no acute liver failure and no evidence of decompensated cirrhosis\u002Fportal hypertension; ASA Physical Status (American Society of Anesthesiologists classification) ≤ IV.\n5. Infection and transmissible diseases: No evidence of active infection; no active tuberculosis; HIV\u002FHBV\u002FHCV status meeting the center's transplant requirements (e.g., undetectable viral load, noticeability per center policy).\n6. Rehabilitation potential and support: Demonstrates postoperative rehabilitation potential (able to cooperate with training) and has reliable caregiving support (at least one primary caregiver).\n\n【2】Exclusion Criteria\n\n1. Informed consent\u002Fadherence: Refusal of or withdrawal of informed consent; investigator judgment that the participant cannot complete follow-up or has recurrent severe non-adherence.\n2. Transplant type: Re-transplantation, multi-organ transplantation, or planned lobar lung transplantation.\n3. Recent major cardiovascular\u002Fcerebrovascular events: Acute coronary syndrome\u002Fmyocardial infarction or stroke within the past 30 days.\n4. Severe organ dysfunction\u002Facute failure: LVEF \\\u003C40%; eGFR \\\u003C40 mL\u002Fmin\u002F1.73 m²; acute liver failure or decompensated cirrhosis\u002Fportal hypertension; acute kidney failure requiring dialysis with low likelihood of recovery; significant preoperative neuropsychiatric disorders or altered consciousness.\n5. High risk of severe infection: Septic shock; active extrapulmonary or disseminated infection; active tuberculosis; detectable HIV viral load (or otherwise not meeting the center's transplant criteria).\n6. High bleeding risk: Severe bronchiectasis in which preoperative vascular intervention has not been performed or bleeding risk cannot be adequately mitigated.\n7. Malignancy: Active malignancy or malignancy associated with a high risk of recurrence or cancer-related mortality.\n8. Extreme body habitus: BMI ≥35 kg\u002Fm² or BMI \\\u003C16 kg\u002Fm²; or a confirmed diagnosis of severe chest wall deformity or spinal deformity.\n9. Substance use\u002Fdependence: Current use of cigarettes, e-cigarettes\u002Fvaping, smoked cannabis, or intravenous drug use.\n10. Tubeless\u002Fspontaneous-breathing strategy not safely feasible: The anesthesia team determines that a difficult airway is anticipated or that laryngeal mask airway (LMA)\u002Fnon-intubated airway management is unsafe (e.g., expected intraoperative airway difficulty, pharyngeal\u002Flaryngeal stenosis unsuitable for LMA), including but not limited to: Mallampati class \\>III, mouth opening \\\u003C3 cm, thyromental distance \\\u003C5 cm, or significant airway anatomical variation (e.g., anomalous right upper lobe bronchial takeoff in candidates for right lung transplantation) deemed difficult to manage safely with an LMA or single-lumen airway.\n11. Donor\u002Fdonor-lung limitations: Donor age \\>60 years; donor mechanical ventilation \\>14 days; positive donor-lung airway culture deemed unacceptable by the transplant team.\n12. Protected populations: Pregnant or breastfeeding women.",{"count":394,"type":23},110,[26],"The goal of this study is to learn whether a spontaneous-breathing (\"tubeless\") anesthesia and surgery strategy can improve early recovery and remain safe for adults who receive a lung transplant. This strategy aims to help lung transplant recipients maintain spontaneous breathing as much as possible during and after surgery, avoid tracheal intubation with invasive mechanical ventilation and deep sedation, and thereby support faster recovery while maintaining postoperative survival and safety. All participants will receive lung transplantation supported by the same spontaneous-breathing (\"tubeless\") strategy. Researchers plan to enroll about 110 participants at several hospitals in China. A separate study team will review the main outcomes using predefined study rules.\n\nThe main questions this study aims to answer are: The main questions this study aims to answer are: among adult lung transplant recipients, does an anesthesia-surgical strategy that preserves spontaneous breathing improve early postoperative recovery while remaining safe during the first 30 days after surgery? The study will focus on the need for postoperative invasive mechanical ventilation, length of postoperative hospital stays, and in-hospital mortality.\n\nParticipants will: Complete screening tests and assessments before surgery (up to about 30 days before the transplant). Undergo lung transplantation using a standardized approach that aims to keep spontaneous breathing function, often using a laryngeal mask airway instead of a breathing tube. Receive pain and cough control measures (such as local anesthesia or nerve block anesthesia) and close monitoring during and after surgery. Receive standard postoperative care. If safety concerns arise, the clinical team will use invasive mechanical ventilation or extracorporeal membrane oxygenation when needed. Be followed during the hospital stay and for 90 days after surgery to record recovery, complications, and readmissions.",[337],[339,263],{"date":343,"type":43},{"date":401,"type":23},"2026-01-10",{"date":403,"type":23},"2027-01-30",{"name":49,"class":50},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":208,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":412,"targetDuration":4,"studyType":24,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":421,"locationsCount":4},"100621999","clinical-study-of-shr-a1811-combined-with-pertuzumab-as-second-line-therapy-in-patients-with-her2-altered-advanced-nsclc-100621999","NCT07377916","Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC","A Prospective, Single-Arm, Exploratory Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Aged 18-75 years\n* Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) (AJCC 9th edition)\n* Pathologically documented HER2 mutation, amplification, or overexpression\n* Received ≥1 prior line of systemic anti-cancer therapy for advanced\u002Fmetastatic disease\n* There is at least one measurable lesion according to RECIST V1.1 criteria\n* ECOG score of 0 or 1.\n* The expected survival is ≥12 weeks\n\nExclusion Criteria:\n\n* There are untreated or active central nervous system (CNS) tumor metastases\n* Has unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to NCI-CTCAE version 5.0 grade ≤ 1.\n* Pleural, ascites, or pericardial effusion requiring intervention occurred within 14 days prior to initial administration\n* Systemic antitumor therapy was performed 4 weeks prior to study initiation\n* Subjects who have previously received HER2-targeted therapy (excluding pan-HER tyrosine kinase inhibitors) or antibody-drug conjugates with a topoisomerase I inhibitor payload.\n* Use of strong CYP3A4, CYP2D6, P-gp, or BCRP inhibitors or inducers within less than 5 drug half-lives prior to the first dose.\n* Has active infection requiring systemic treatment.",{"count":376,"type":23},[26],"The study enrolled patients with advanced or metastatic NSCLC harboring HER2 mutations, amplification, or overexpression who had progressed after ≥1 prior lines of anticancer therapy. After enrollment, participants received treatment with rezetamab plus pertuzumab until disease progression, intolerable toxicity, withdrawal of consent, or other conditions requiring treatment discontinuation.",[104],"2026-01-28",{"date":364,"type":43},{"date":419,"type":23},"2026-02-15",{"date":215,"type":23},{"name":49,"class":50},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":24,"phases":431,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":51},"100617439","phase-1-nk-cell-therapy-combined-with-pd-1-antibody-and-platinum-based-chemotherapy-as-neoadjuvant-therapy-in-resectable-nsclc-100617439","NCT07318636","NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC","An Open-Label, Single-Arm Study Evaluating the Safety and Efficacy of NK010 Cell Injection Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the written informed consent form (ICF).\n* Male or female patients aged ≥18 years.\n* Histologically and\u002For cytologically confirmed resectable stage IB to IIIA non-small cell lung cancer (NSCLC) according to AJCC 8th edition.\n* Treatment-naïve NSCLC (no prior systemic anticancer therapy).\n* No sensitizing EGFR mutations (exon 19 deletion, exon 21 L858R) and no ALK gene rearrangement.\n* At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Estimated life expectancy of more than 6 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Adequate bone marrow, liver, and renal function.\n* Female participants of childbearing potential must have a negative pregnancy test prior to initiation of study treatment.\n\nExclusion Criteria:\n\n* Prior receipt of any systemic anticancer therapy.\n* Known sensitizing EGFR mutations or ALK gene rearrangements.\n* Active, known, or suspected autoimmune disease.\n* Interstitial lung disease.\n* Any medical condition, therapy, or laboratory abnormality that, in the opinion of the investigator, could confound the study results, interfere with the participant's ability to comply with study procedures, or is not in the best interest of the participant.\n* Locally advanced unresectable or metastatic NSCLC.\n* Major cardiovascular events, unstable arrhythmia, or unstable angina within 3 months prior to study treatment initiation.\n* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use effective contraception during the study.\n* Any other condition judged by the investigator to make the participant unsuitable for clinical trial participation.",{"count":430,"type":23},10,[432],"PHASE1","This open-label, single-arm study is designed to evaluate the safety and preliminary efficacy of NK010 cell injection combined with a PD-1 antibody and platinum-based chemotherapy as neoadjuvant therapy in patients with resectable non-small cell lung cancer (NSCLC). The study aims to assess the safety profile, feasibility of administration, and potential antitumor activity of this combination regimen.",[435],"Resectable Non-small Cell Lung Cancer",[104],"2026-01-04",{"date":439,"type":43},"2026-01-06",{"date":441,"type":23},"2026-01-20",{"date":443,"type":23},"2027-12-30",{"name":49,"class":50},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":24,"phases":455,"briefSummary":456,"conditions":457,"keywords":461,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":471,"locationsCount":51},"100616305","phase-2-golidocitinib-for-refractory-immune-related-hematologic-toxicities-of-advanced-lung-cancer-100616305","NCT07303881","Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer","A Clinical Study Evaluating the Safety and Efficacy of Golidocitinib in Patients With Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer","JACKPOT22","Inclusion Criteria:\n\n1. Able to provide a signed and dated informed consent form, including compliance with the Informed Consent Form (ICF) and the requirements and limitations listed in this protocol.\n2. The subject is ≥18 years of age at the time of signing the ICF.\n3. Has not experienced disease progression in the past two weeks and has a Eastern Cooperative Oncology Group (ECOG) score of 0-2, with a predicted survival of ≥12 weeks.\n4. Pathologically or cytologically confirmed locally advanced (American Joint Committee on Cancer, AJCC 8th edition IIIB and IIIC stages) or metastatic (stage IV) non-small cell lung cancer, or extensive-stage small cell lung cancer (AJCC 8th edition TNM staging of lung cancer stage IV, or T3-4 disease caused by multiple pulmonary nodules with excessive disease spread, or tumor\u002Fnodule size too large for a tolerable radiation therapy plan).\n5. Patients confirmed by an accredited local laboratory to lack any therapeutically targeted driver gene mutations, i.e., driver gene-negative subjects.\n6. Patients experiencing grade ≥3 refractory hematologic toxicity (white blood cell count \\\u003C2.0 × 10⁹\u002FL or\u002Fand absolute neutrophil count \\\u003C1.0 × 10⁹\u002FL or\u002Fand platelet count \\\u003C50 × 10⁹\u002FL or\u002Fand hemoglobin \\\u003C8.0 g\u002FdL, specific hematologic parameters are detailed in Appendix D), during treatment with immune checkpoint inhibitors (including monotherapy or combination therapy), and the toxicity is considered to be immune-related. Refractory toxicity is defined in two main ways: ① Resistance to conventional treatment: No significant improvement in hematologic toxicity after at least 3 days of supportive care including the use of hormones (e.g., methylprednisolone ≥1 mg\u002Fkg\u002Fd), hematopoietic growth factors (e.g., G-CSF, TPO), and\u002For blood transfusions; ② Positive antinuclear antibody profile indicating anti-SSA antibodies and\u002For Ro52 antibodies, suggesting an immune-mediated mechanism.\n7. Patients with brain metastases must be asymptomatic or have been treated and have stable disease after discontinuation of steroids and anticonvulsants. Patients suspected of having brain metastases at screening should undergo brain CT\u002FMRI before study enrollment.\n8. At least one measurable lesion (as defined in RECIST 1.1): a lesion that has not undergone radiotherapy, has a long diameter ≥10 mm (short diameter ≥15 mm for lymph node lesions), and can be accurately and repeatedly measured from baseline on CT or MRI; and a measurable lesion outside the central nervous system.\n9. Adequate organ system functional reserve, summarized as follows:\n\n   * Total bilirubin ≤1.5×ULN; if Gilbert's syndrome (unconjugated hyperbilirubinemia) is present, total bilirubin should be ≤3×ULN.\n   * ALT and AST ≤2.5×ULN. For patients with documented liver metastases, AST and ALT levels ≤5×ULN.\n   * Creatinine clearance, calculated using the Cockcroft-Gault method, \\>60 ml\u002Fmin for patients treated with cisplatin and \\>45 ml\u002Fmin for patients treated with carboplatin.\n   * Urinalysis shows less than 2+ protein in urine, or 24-hour urine protein quantification \\\u003C1g.\n   * Good coagulation function, defined as International Normalized Ratio (INR) and\u002For Prothrombin Time (PT) ≤1.5 times the ULN and\u002For Activated Partial Thromboplastin Time (APTT) ≤1.5 of the upper limit of normal; if the subject is receiving anticoagulation therapy, PT is acceptable as long as it is within the range intended for use with the anticoagulant.\n   * Serum amylase ≤1.5 times the ULN and\u002For serum lipase ≤1.5 times the ULN.\n   * Echocardiography (ECHO) shows a left ventricular ejection fraction (LVEF) ≥55%.\n10. Women of Childbearing Potential (WOCBP) must undergo a urine and\u002For serum pregnancy test (if the urine test cannot confirm a negative result) within 7 days prior to the first dose of the study drug, and the result must be negative; WOCBP or male subjects and their WOCBP partners should agree to use effective contraception from the signing of the ICF until 6 months after the last dose of the study drug. k. Participants should be able to understand the study protocol and voluntarily comply with the study and follow-up.\n\nExclusion Criteria:\n\na. An active autoimmune disease requiring systemic treatment (e.g., use of disease-modifying medications, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapies (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment.\n\nb. Prior to the first dose, any other form of immunosuppressive therapy other than corticosteroids (e.g., TNF-α inhibitors, mycophenolate mofetil, gamma globulin, rituximab, other JAK inhibitors, etc.) was received for hematologic toxicity.\n\nc. Spinal cord compression or meningeal metastases are present. d. Any of the following medical histories:\n\n* Currently participating in an interventional clinical trial, or having received other investigational drugs or used investigational devices within 4 weeks prior to the first dose; any drug still in development requires a 5-half-life washout (or discussion with the research team);\n* Underwent major surgery (excluding diagnostic or biopsy, excluding vascular access) within 4 weeks prior to the first dose, or is expected to undergo major surgery during the study;\n* Received palliative radiation therapy within 2 weeks prior to the first dose;\n* Have experienced a serious arterial\u002Fvenous thrombotic event within 6 months prior to the first dose, including cerebrovascular accidents (e.g., history of stroke or intracranial hemorrhage), deep vein thrombosis, and pulmonary embolism;\n* Currently receiving (or unable to discontinue at least 1 week prior to the first dose) any known potent inducer or inhibitor of CYP3A, herbal supplements, or foods;\n* Have experienced a grade CTCAE \\> 1 adverse event (excluding any degree of alopecia and hematologic toxicity) due to prior treatment prior to the first dose. e. Has received a solid organ or blood system transplant (e.g., a previous allogeneic bone marrow transplant).\n\n  f. Has a history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring corticosteroid therapy, or currently has active interstitial lung disease (including interstitial lung changes), or immune-mediated pneumonitis caused by immunotherapy.\n\n  g. Has been diagnosed with another malignancy within 5 years prior to the first dose, excluding clinically cured basal cell carcinoma, squamous cell carcinoma, and\u002For radically resected carcinoma in situ.\n\n  h. Has received a live vaccine, including attenuated live vaccines, excluding inactivated vaccines, within 30 days prior to the first dose.\n\n  i. Has known active tuberculosis, such as a positive tuberculin (PPD) test (induration diameter \\> 10 mm), a positive T-SPOT test, tuberculous lesions on chest X-ray\u002FCT, or other positive results found according to routine clinical screening (excluding those cured by investigator assessment after standard anti-tuberculosis treatment).\n\n  j. Subjects with pre-existing, uncontrollable severe infectious diseases must be excluded. If an infectious disease occurred within two months prior to the first dose, its control must be assessed by the research team to determine eligibility for enrollment.\n\n  k. Subjects with active infections, including but not limited to hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) (see table below), and active COVID-19 infection (determined by the investigator to be clinically significant, with signs or symptoms). COVID-19 testing will be based on local practice.\n\n  l. Meeting any of the following cardiac criteria:\n* Congestive heart failure (CHF) classified as \\>II by the New York Heart Association (NYHA);\n* Clinically significant valvular heart disease, hypertrophic or constrictive cardiomyopathy;\n* Any clinically significant abnormality on resting ECG, such as complete left bundle branch block, second\u002Fthird-degree atrioventricular block, or PR interval \\>250 msec;\n* Average calibrated QTcF \\>470 msec on three resting ECGs during the screening period;\n* Any factor that could increase the risk of QT interval prolongation or arrhythmic events (e.g., heart failure, hypokalemia, congenital long QT syndrome, or a first-degree relative with long QT syndrome or a family history of unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval);\n* Ventricular arrhythmias requiring treatment;\n* An acute myocardial infarction (AMI), the onset of unstable angina, or a new onset of angina within 6 months prior to administration.\n\n  m. Hypersensitivity to the study drug or any component thereof. n. Intractable nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing medication, intestinal obstruction, or a history of bowel resection that may prevent adequate absorption of the study drug.\n\n  o. Pregnancy or lactation. p. Known bleeding diathesis, i.e., hemophilia or von Willebrand disease. q. Investigator assessment indicating a serious or uncontrolled systemic disease (including poorly controlled hypertension and bleeding disorders) that precludes participation in the clinical study or may lead to poor adherence.",{"count":454,"type":23},16,[178],"This study is a single-arm clinical trial designed to evaluate the safety and efficacy of golidocitinib in patients with refractory, immune-related hematologic toxicity in advanced lung cancer.",[458,459,460],"IrAE","Hematologic Disorder","Lung Cancer (Locally Advanced or Metastatic)",[462,463,464],"Immune-related hematologic toxicities","irAE","Lung cancer","2025-12-12",{"date":467,"type":43},"2025-12-26",{"date":469,"type":23},"2026-02",{"date":75,"type":23},{"name":49,"class":50},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":24,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":4},"100601003","non-intubated-versus-intubated-anesthesia-in-thoracoscopic-esophagectomy-for-esophageal-cancer-100601003","NCT07104838","Non-intubated Versus Intubated Anesthesia in Thoracoscopic Esophagectomy for Esophageal Cancer","Efficacy and Safety of Non-intubated Versus Intubated Anesthesia in Thoracoscopic Radical Esophagectomy for Esophageal Cancer: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Diagnosed with resectable middle or lower thoracic esophageal squamous cell carcinoma or adenocarcinoma (clinical stage I-III)\n* Scheduled to undergo thoracoscopic esophagectomy\n* American Society of Anesthesiologists (ASA) score ≤ III\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n* Preoperative pulmonary function test with FEV₁ ≥ 50% predicted\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Severe risk of aspiration due to reflux, gastric retention, or hiatal hernia\n* Body mass index (BMI) ≥ 30 kg\u002Fm²\n* Extensive pleural adhesions discovered preoperatively\n* History of upper thoracic or intrathoracic surgery\n* Pregnancy or lactation\n* Known allergy or intolerance to anesthetic agents",{"count":480,"type":23},500,[26],"This is a prospective, single-center, non-inferiority randomized controlled trial designed to evaluate the perioperative safety and feasibility of non-intubated spontaneous ventilation anesthesia (NIV) compared to conventional intubated mechanical ventilation anesthesia (IMV) in patients undergoing thoracoscopic esophagectomy for esophageal cancer. The study will be conducted at the First Affiliated Hospital of Guangzhou Medical University and aims to assess whether the non-intubated approach can offer comparable or better outcomes in terms of intraoperative and postoperative complications, anesthetic drug consumption, recovery parameters, and overall postoperative rehabilitation.\n\nEligible patients aged 18 to 75 years with resectable middle or lower thoracic esophageal squamous cell carcinoma or adenocarcinoma (stage I-III) will be randomly assigned (1:1) to receive either NIV using a laryngeal mask airway or IMV with a double-lumen endotracheal tube. Both groups will undergo the same thoracoscopic and laparoscopic surgical procedures, and anesthesia will be managed with standardized protocols. The primary outcome is the incidence of intraoperative and postoperative complications, including hypoxemia, hypercapnia, respiratory failure, and the need for conversion to intubation. Secondary outcomes include anesthetic drug dosage, intraoperative hemodynamic stability, postoperative pain scores, time to ambulation, length of hospital stay, and 30-day readmission rate.\n\nThis trial complies with the Declaration of Helsinki. Written informed consent will be obtained from all participants prior to enrollment.",[484],"Esophageal Cancer (EsC)","2025-09-23",{"date":487,"type":43},"2025-09-25",{"date":489,"type":23},"2025-10-01",{"date":491,"type":23},"2026-12-01",{"name":49,"class":50},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100606016","observational-study-on-the-impact-of-herpes-zoster-vaccine-on-the-incidence-of-herpes-zoster-and-survival-in-lung-cancer-patients-100606016","NCT07170059","Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients","An Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients","Inclusion Criteria:\n\n* 1.Male or female patients \\>=18 years of age; 2.Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received herpes zoster vaccine\n\nExclusion Criteria:\n\n* Patients having other factors that preventing researchers from enrollment them.",{"count":480,"type":23},"To evaluate the impact of herpes zoster vaccine on the incidence of herpes zoster and survival in lung cancer patients, and to explore its preventive effect and safety.",[503],"Lung Cancer","2025-09-07",{"date":506,"type":43},"2025-09-12",{"date":489,"type":23},{"date":509,"type":23},"2030-10-01",{"name":49,"class":50},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":24,"phases":520,"briefSummary":521,"conditions":522,"keywords":525,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":536,"locationsCount":51},"100604507","phase-2-nebulized-inhalation-of-recombinant-human-p53-adenovirus-injection-for-treatment-of-multiple-ground-glass-lung-nodules-a-single-arm-clinical-study-100604507","NCT07150416","Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study","A Single-Arm Clinical Study of Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection (Gendicine) for Treatment of Multiple Ground-Glass Lung Nodules","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. CT scan confirms the presence of multiple ground-glass nodules (GGNs), with at least one nodule measuring between 0.5 cm and 3.0 cm in diameter.\n3. At least one GGN is confirmed as malignant or precancerous (e.g., atypical adenomatous hyperplasia, adenocarcinoma in situ) by histopathology or cytology.\n4. Life expectancy ≥ 12 weeks.\n5. Adequate pulmonary function tests (FEV1 ≥ 70% of predicted value).\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of other active malignancies within the past 5 years.\n3. Severe cardiac, hepatic, or renal dysfunction (e.g., NYHA class III\u002FIV heart failure, ALT\u002FAST \\> 3×ULN, Cr \\> 1.5×ULN).\n4. Uncontrolled systemic infection or immunodeficiency diseases.\n5. Participation in another interventional clinical trial within 4 weeks prior to enrollment.\n6. Known hypersensitivity to any component of the recombinant human p53 adenovirus injection.",{"count":519,"type":23},38,[178],"This study aims to evaluate the safety and efficacy of nebulized inhalation of Recombinant Human Ad-p53 Injection (Gendicine®) for the treatment of multiple ground-glass lung nodules. This is a single-arm, open-label clinical study conducted at The First Affiliated Hospital of Guangzhou Medical University in China. We plan to enroll approximately 38 patients who have been diagnosed with multiple ground-glass nodules. All participants in this study will receive the nebulized Gendicine® treatment. After the treatment, we will monitor changes in the nodules through regular chest CT scans and record any potential treatment-related reactions to determine if this novel therapy is safe and effective. This study has been approved by the hospital's Ethics Committee.",[523,287,524],"Multiple Pulmonary Ground-Glass Nodules","Precancerous Conditions",[526,527,528,529],"p53 gene therapy","nebulized inhalation","Gendicine","Single-Arm Trial","2025-08-25",{"date":532,"type":43},"2025-09-02",{"date":489,"type":23},{"date":535,"type":23},"2027-02-01",{"name":49,"class":50},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":4},"100603864","an-observational-study-on-the-impact-of-the-23-valent-pneumonia-vaccine-on-lung-cancer-patients-100603864","NCT07142057","An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients","An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients","Inclusion Criteria:\n\n1. Male or female patients \\>=18 years of age;\n2. Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;\n3. Never received pneumococcal vaccine\n\nExclusion Criteria:\n\nPatients having other factors that preventing researchers from enrollment them.",{"count":480,"type":23},"To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.",[547],"LUNG CANCER","2025-08-19",{"date":550,"type":43},"2025-08-26",{"date":552,"type":23},"2025-09-01",{"date":554,"type":23},"2030-09-01",{"name":49,"class":50},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":118,"sex":18,"minAge":562,"maxAge":331,"enrollmentInfo":563,"targetDuration":4,"studyType":24,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":4},"100598941","a-randomized-controlled-trial-evaluating-the-effectiveness-of-a-novel-risk-stratified-screening-strategy-for-lung-cancer-100598941","NCT07078032","A Randomized Controlled Trial Evaluating the Effectiveness of a Novel Risk-Stratified Screening Strategy for Lung Cancer","Inclusion Criteria:\n\n1. Residents with local household registration residing continuously in the region for ≥3 years.\n2. Aged 40-74 years at enrollment.\n\nExclusion Criteria:\n\n1. Prior diagnosis of lung cancer (histologically\u002Fcytologically confirmed)\n2. Currently receiving active treatment for any malignancy.\n3. Presence of severe comorbidities with life expectancy \\\u003C5 years\n4. Participation in any lung cancer screening program within 5 years.\n5. Functional dependency (ADL score ≤2) OR unwillingness to comply with protocol-required follow-up.\n6. Declined to provide written informed consent.","40 Years",{"count":564,"type":23},60000,[26],"A nationwide population-based multi-center RCT enrolling ≥60,000 eligible residents to compare screening effectiveness between risk-prediction-model-driven and traditional guideline-based high-risk lung cancer screening strategies.",[568],"Lung Cancer Screening","2025-07-12",{"date":571,"type":43},"2025-07-22",{"date":573,"type":23},"2025-07",{"date":575,"type":23},"2028-11",{"name":49,"class":50},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":118,"sex":18,"minAge":562,"maxAge":331,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":586,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":51},"100592065","the-impact-of-ai-assistance-on-radiologist-performance-and-healthcare-costs-in-ldct-based-lung-cancer-screening-100592065","NCT06988579","The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening","Evaluation of AI-Assisted Versus Conventional Human Reading for Lung Cancer Screening in Community-Based Settings: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 45-74 years\n2. Permanent resident of participating study communities\n3. No prior history of lung cancer and no lung cancer screening within the past 3 months\n4. Able to comprehend and voluntarily sign informed consent, with willingness to participate in long-term follow-up\n\nExclusion Criteria:\n\n1. Individuals with a confirmed diagnosis of lung cancer\n2. Those with severe comorbidities contraindicating CT imaging\n3. Inability to understand study protocols or provide informed consent due to cognitive impairment\n4. Concurrent participation in other clinical trials that may interfere with study outcomes\n5. Unable to comply with follow-up requirements",{"count":585,"type":23},7294,[26],"AI diagnostic systems show great promise for improving lung cancer screening in community healthcare settings. While not originally designed for primary care, these tools demonstrate capabilities in nodule detection and workflow optimization. However, their effectiveness in resource-limited community centers requires thorough evaluation.\n\nThis RCT compares AI-assisted versus manual CT interpretation across community health centers. Expert radiologists will establish reference standards, while an independent committee blindly evaluates cases from both groups. The study assesses diagnostic accuracy, operational efficiency, and cost-effectiveness, with blinded analysts resolving discrepancies through consensus to ensure reliable results.",[503,589,38],"Artificial Intelligence (AI)","2025-06-23",{"date":592,"type":43},"2025-06-26",{"date":594,"type":43},"2024-07-01",{"date":596,"type":23},"2026-01-07",{"name":49,"class":50},""]